E-Cigarette Firm Targets Harm Reduction In Therapeutic Claim
This article was originally published in The Tan Sheet
Executive Summary
CN Creative’s plan to include harm reduction with smoking cessation in claims for its Nicadex electronic cigarette was key to Advent Life Sciences investing in the firm, which is prepared to ask U.K. regulators for approval this summer before applying in the U.S.
You may also be interested in...
Looming E-Cigarette Regulation Could Shift Cessation Playing Field
Approval as smoking cessation products is an expensive option for e-cigarette firms due to the costs of preparing and submitting an NDA to FDA’s drug center. Regulation under the agency’s tobacco center could lead to modified risk status, but might make the NDA route more appealing.
Looming E-Cigarette Regulation Could Shift Cessation Playing Field
Approval as smoking cessation products is an expensive option for e-cigarette firms due to the costs of preparing and submitting an NDA to FDA’s drug center. Regulation under the agency’s tobacco center could lead to modified risk status, but might make the NDA route more appealing.
Looming E-Cigarette Regulation Could Shift Cessation Playing Field
Approval as smoking cessation products is an expensive option for e-cigarette firms due to the costs of preparing and submitting an NDA to FDA’s drug center. Regulation under the agency’s tobacco center could lead to modified risk status, but might make the NDA route more appealing.